You just read:

Regeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease

News provided by

Regeneron Pharmaceuticals, Inc.

Jan 09, 2020, 07:00 ET